TMCnet News

Research and Markets: Hyperandrogenism Global Clinical Trials Review, H2, 2015
[November 26, 2015]

Research and Markets: Hyperandrogenism Global Clinical Trials Review, H2, 2015


Research and Markets (http://www.researchandmarkets.com/research/885v57/hyperandrogenism) has announced the addition of the "Hyperandrogenism Global Clinical Trials Review, H2, 2015" report to their offering.

This new report provides an overview of Hyperandrogenism clinical trials scenario. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. The trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe and the database undergoes periodic update by dynamic process.

Scope of the report:

  • Provides a snapshot of the global clinical trials landscae.
  • Provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.
  • Reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
  • Provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment.
  • Provides enrollment trends for the past five years.
  • Provides latest news for the past three months.


Reasons to buy:

  • Assists in formulating key business strategies with regards to investment.
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market.
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials.
  • Facilitates clinical trial assessment of the indication on a global, regional and country level.

Companies Mentioned:


  • Shire Plc
  • Stragen Holding
  • Sermes
  • Sandoz International GmbH
  • DM Contact Management
  • Cosmo Pharmaceuticals S.p.A
  • Catalysis, S.L.
  • Bayer AG
  • Barij Essence Pharmaceutical Company
  • A. Menarini Industrie Farmaceutiche Riunite Srl

For more information visit http://www.researchandmarkets.com/research/885v57/hyperandrogenism


[ Back To TMCnet.com's Homepage ]